# Umoja BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/umoja-biopharma

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Website: www.umoja-biopharma.com
- Total disclosed funding: $363M
- Latest round: Series C (Oct 3, 2024)
- Investors on record: 18

## About

Established in 2019 and based in Washington, US, Umoja BioPharma, Inc. operates as a biopharmaceutical company. The company was founded by its CEO, Dr. Andrew Scharenberg, CTO, Dr. Ryan Crisman, and Scientific Advisory Board Co-Chairs Michael Jensen and Philip Low. In January 2025, Umoja BioPharma, Inc. raised USD 100 million in series C funding co-led by new investor Double Point Ventures and returning investor Data Collective, with participation from other returning investors Cormorant Asset Management, MPM BioImpact, Qiming Venture Partners, RTW Investments, Alexandria Venture Investments, SB Investment Advisers, CaaS Capital Management, and Emerson Collective. New investors ARK Invest, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Foundation, and other unspecified investors also participated in the round.

Umoja BioPharma develops integrated cellular immunotherapy that helps in treating tumors through retooling a patient's immune system. The company has two lead pipeline programs under its portfolio: TumorTag UB-TT170 and VivoVec UB-VV100. TumorTag UB-TT170 is used for controlling folate receptors expressing solid tumors, and VivoVec UB-VV100 is being developed to treat patients with CD19+ hematological cancers.

The company will use the January 2025 funding to support the development of its medical pipeline.

## Funding rounds

- Series C, Oct 3, 2024, $100M — Alexandria Venture Investments, Qiming Venture Partners, MPM BioImpact, University of Minnesota Foundation, DCVC, RTW Investments, Cormorant Asset Management, SB Investment Advisers, Emerson Collective, K2 HealthVentures, Ark Invest, CaaS Capital Management, Myeloma Investment Fund, Double Point Ventures
- Series B, Jun 15, 2021, $210M — Temasek Holdings, Alexandria Venture Investments, Qiming Venture Partners, MPM BioImpact, Casdin Capital, DCVC, RTW Investments, Cormorant Asset Management, SB Investment Advisers, Emerson Collective, Presight Capital, SVB Leerink, CaaS Capital Management
- Series A, Nov 18, 2020, $53M — Qiming Venture Partners, MPM BioImpact
- Seed, Nov 21, 2019 — Casdin Capital, DCVC

## Investors

- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Seed, Series B
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series B, Series C
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- Temasek Holdings — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series B, Series C
- Emerson Collective — Series B, Series C
- Presight Capital — Series B
- SVB Leerink — Series B
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series B, Series C
- University of Minnesota Foundation — Series C
- K2 HealthVentures (https://capitalatlas.ai/funds/k2-healthventures) — Series C
- Ark Invest (https://capitalatlas.ai/funds/ark-invest) — Series C
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series C
- Double Point Ventures (https://capitalatlas.ai/funds/double-point-ventures) — Series C